Date: 2015-06-03
Type of information: Restructuring
Compound: vaccine business
Company: Takeda Pharmaceutical (Japan)
Therapeutic area: Infectious diseases
Type agreement: restructuring
Action mechanism:
Disease:
Details: * On June 3, 2015, Takeda Pharmaceutical announced that it will consolidate its Vaccine Business Unit (VBU) operations by establishing global and regional hubs as the organization continues to grow and advance its important vaccine programs in norovirus, dengue and seasonal influenza. The Boston/Cambridge, Massachusetts area, and Zurich, Switzerland will serve as VBU’s global hubs for the vaccine business outside of Japan. VBU will maintain regional hubs in Singapore and in Brazil and will operate
manufacturing sites in Hikari, Japan; Durham, North Carolina and Singen, Germany. In the U.S., all vaccine activities with the exception of manufacturing will move to the new global hub in the Boston/Cambridge area. This co-location will significantly enhance communication and collaboration across VBU’s divisions, and will allow VBU to leverage Takeda’s significant R&D presence in Cambridge. It will also provide access to the area’s remarkable biotech/pharmaceutical ecosystem and talent base.
Takeda will close its vaccine site in Bozeman, Montana, which it obtained through the acquisition of LigoCyte Pharmaceuticals in 2012, as well as the Madison, Wisconsin and Fort Collins, Colorado sites, which came to Takeda through the acquisition of Inviragen, Inc. in 2013. In addition, vaccine activities in Deerfield, Illinois, which currently serves as the global headquarters for VBU, will shift to the Boston/Cambridge area. This transition will occur in phases over the next two years, with the completion of U.S. consolidation by mid-2017.
Financial terms:
Latest news:
